TAFAZZIN Chromosome X
Tafazzin, phospholipid-lysophospholipid transacylase
Upload your DNA to see your personal genotypes for variants in TAFAZZIN.
What This Gene Does
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
Associated Conditions (11)
Primary dilated cardiomyopathy
3-Methylglutaconic aciduria type 2
Endocardial fibroelastosis
Cardiovascular phenotype
TAFAZZIN-related disorder
Cardiomyopathy
Primary familial hypertrophic cardiomyopathy
Thyroid cancer
nonmedullary
1
Left ventricular noncompaction cardiomyopathy
Key Variants
RS1057515818
Conflicting classifications of pathogenicity
Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis
Health Risk
RS1223065368
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS1298362744
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS1557194488
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS200405157
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS200909606
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis, Primary dilated cardiomyopathy
Health Risk
RS2522937677
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS2522986801
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2
Health Risk
RS374146054
Conflicting classifications of pathogenicity
Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype
Health Risk
RS397515739
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515741
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515742
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
All Variants (109)
| RSID | Category | Clinical Significance | Conditions |
|---|---|---|---|
| RS794729174 | Health Risk | Pathogenic | — |
| RS876661038 | Health Risk | Pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS878853656 | Health Risk | Pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1085307797 | Health Risk | Pathogenic/Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS132630277 | Health Risk | Pathogenic/Likely pathogenic | 3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2 |
| RS1557191170 | Health Risk | Pathogenic/Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1569552936 | Health Risk | Pathogenic/Likely pathogenic | Cardiomyopathy, 3-Methylglutaconic aciduria type 2, Cardiomyopathy |
| RS2068606932 | Health Risk | Pathogenic/Likely pathogenic | Cardiomyopathy, 3-Methylglutaconic aciduria type 2, Cardiomyopathy |
| RS2148185111 | Health Risk | Pathogenic/Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |